Tag - Immusoft

Immusoft Acquires Exclusive, Worldwide Rights to Intellectual Property for Genome Edited Primary B Cells from the University of Minnesot

Antonette Ho2023-03-28T23:35:51-04:00Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for compositions of matter and methods to make and use genome edited primary B cells. The parent patent application is titled, “Genome Edited Primary B cell and Methods of Making and Using.” The IP includes proprietary methods that...

Immusoft Awarded $8M in Funding from the California Institute for Regenerative Medicine (CIRM) for MPS I Clinical Program

Antonette Ho2023-02-14T20:00:47-05:00Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company an $8M grant. This funding will support a Phase I study to evaluate the safety and tolerability of ISP-001 (for delivery of alpha-L-iduronidase, or IDUA) in MPS I a rare, childhood genetic disease. The Investigational New Drug Application for...

Immusoft Announces FDA Clearance of IND Application for ISP-001 for MPS I, the First Engineered B Cell Therapy to Enter into Clinical Trials

Ziad2022-11-25T13:59:44-05:00Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I. The open IND enables Immusoft to initiate a Phase 1 clinical study. This milestone is both significant for Immusoft and historic in the field of cell and gene therapies, as ISP-001 will be the first engineered B...

Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)

Ziad2022-11-25T14:00:10-05:00Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP-002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options. MPS II is a rare genetic disease in children, which causes...

Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers

Ziad2022-11-25T14:00:11-05:00Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing $4.1 million in a therapy aimed at helping patients who have failed standard therapy. The CIRM Board also approved investing $44,101,935 in 11 projects as part of...

Takeda bets up to $900M on Immusoft’s cell therapies for neurometabolic disorders

Ziad2022-11-25T14:00:11-05:00               Immusoft has inked its first Big Pharma collaboration in a deal with biotech's best friend Takeda worth up to $900 million that sees the pair work on cell therapies in rare inherited disorders. The pact will focus on neurometabolic disorders, Immusoft said Wednesday. The deal comes as the Seattle-based biotech nears the clinic for the first time in its decadelong journey working on sustained protein delivery for rare diseases. Read more >>

Immusoft Announces Formation of Scientific Advisory Board

Ziad2022-11-25T14:00:29-05:00 Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs. The SAB will work closely with the Immusoft leadership team to advance and expand its leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered. Read more >>